For research use only
| Cat No. | ABC-TC0099 |
| Product Type | Rat Nerve Cell Lines |
| Cell Type | Fibroblast |
| Species | Rat |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Malignant Glioma |
| Product Code | C-6; C 6; RGC-6; RGC6; RGc6 |
C6 rat glioma cells show fibroblast morphology, tumorigenic with metastasis, overexpress glioma markers, activate PDGFβ and EGFR, mimicking human tumors.
C6 is a rat glioma cell line derived from a N-nitrosomethylurea-induced brain tumor in an adult male Wistar-Furth rat. These cells exhibit fibroblast-like morphology, adhere to culture surfaces, and have a doubling time of 25–30 hours. Cytogenetically, C6 cells display a diploid male karyotype. They overexpress glioma-associated markers including S-100 and GFAP, and activate tumor-relevant signaling pathways such as PDGFβ and EGFR, closely modeling human glioma biology. C6 cells are tumorigenic in immunocompromised mice, with evidence of metastasis to distant organs such as the lungs. They are also susceptible to several neurotropic viruses, including LCMV, HSV, and vaccinia virus, making them suitable for neuro-oncology and viral pathogenesis studies. Furthermore, their enhanced Ras pathway activation in response to extracellular matrix components supports their use in exploring tumor–ECM interactions and glioma invasion mechanisms.
| Product Code | C-6; C 6; RGC-6; RGC6; RGc6 |
| Species | Rat |
| Cat.No | ABC-TC0099 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Disease | Malignant Glioma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Rat Nerve Cell Lines |
The C6 rat glioma cell line serves as a capable model for studying the biology of glioblastoma multiforme (GBM) and related high-grade gliomas. It is widely employed in neuro-oncology research, particularly in drug discovery. Its tumorigenicity enables the creation of orthotopic and subcutaneous xenograft models, facilitating in vivo assessment of drug efficacy, resistance mechanisms, and invasion patterns of therapeutic agents. Researchers use C6’s unique PDGFβ/EGFR pathway activation along with S-100/GFAP overexpression to investigate glioma-stromal interactions, tumor invasiveness, and tumor-induced angiogenesis. Furthermore, its viral susceptibility profile facilitates studies on oncolytic virotherapy and blood-brain barrier dynamics.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
